BR112016017597A2 - Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo - Google Patents
Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpoInfo
- Publication number
- BR112016017597A2 BR112016017597A2 BR112016017597A BR112016017597A BR112016017597A2 BR 112016017597 A2 BR112016017597 A2 BR 112016017597A2 BR 112016017597 A BR112016017597 A BR 112016017597A BR 112016017597 A BR112016017597 A BR 112016017597A BR 112016017597 A2 BR112016017597 A2 BR 112016017597A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- producing
- antigen
- interest
- selecting
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 150000001413 amino acids Chemical group 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14153480 | 2014-01-31 | ||
PCT/NL2015/050054 WO2015115892A1 (en) | 2014-01-31 | 2015-01-30 | Means and methods for producing stable antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016017597A2 true BR112016017597A2 (pt) | 2017-08-08 |
Family
ID=50031190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016017597A BR112016017597A2 (pt) | 2014-01-31 | 2015-01-30 | Métodos para produzir uma célula b, para selecionar pelo menos uma célula b, para produzir anticorpos específicos para um antígeno de interesse e para identificar pelo menos uma mutação na sequência de aminoácido da cadeia pesada e/ou cadeia leve de um anticorpo |
Country Status (8)
Country | Link |
---|---|
US (1) | US10611829B2 (pt) |
EP (1) | EP3099709B1 (pt) |
JP (1) | JP6747975B2 (pt) |
AU (1) | AU2015211480B2 (pt) |
BR (1) | BR112016017597A2 (pt) |
CA (1) | CA2938193C (pt) |
DK (1) | DK3099709T3 (pt) |
WO (1) | WO2015115892A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016014881B1 (pt) * | 2013-12-24 | 2023-03-28 | Kling Biotherapeutics B.V | Métodos para obtenção de uma cultura de célula b ex vivo, para aumentar a vida útil replicativa de uma célula b de coelho e para obtenção de anticorpos, e, uso in vitro de pelo menos uma parte funcional do domínio extracelular de uma proteína galv e de um veículo de dispensa de genes |
KR102037183B1 (ko) * | 2018-02-09 | 2019-10-28 | 엠랩 주식회사 | 스트리밍 미디어에 코멘트를 맵핑하는 시스템 및 방법 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997764A (en) | 1987-04-23 | 1991-03-05 | New York University | Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors |
EP0402402B1 (en) | 1988-02-26 | 1995-12-27 | Worcester Foundation For Biomedical Research, Inc. | Inhibition of htlv-iii by exogenous oligonucleotides |
US5866757A (en) | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
WO1994007367A1 (en) | 1992-09-29 | 1994-04-14 | Apollon, Inc. | Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids |
KR950704482A (ko) | 1992-10-05 | 1995-11-20 | 다알렌 반스톤 | 치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical) |
WO1994017086A1 (en) | 1993-01-25 | 1994-08-04 | Apollon, Inc. | Gene regulation by targeting putative intramolecular triple helix |
US5550019A (en) | 1993-05-26 | 1996-08-27 | La Jolla Cancer Research Foundation | Methods of identifying compounds which alter apoptosis |
US5866755A (en) | 1993-06-14 | 1999-02-02 | Basf Aktiengellschaft | Animals transgenic for a tetracycline-regulated transcriptional inhibitor |
AU679120B2 (en) | 1993-09-03 | 1997-06-19 | Systemix, Inc. | Genetically modified human hematopoietic stem cells and their progeny |
GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
US6001558A (en) | 1997-06-25 | 1999-12-14 | Ortho Clinical Diagnostics, Inc. | Amplification and detection of HIV-1 and/or HIV 2 |
CA2383563A1 (en) | 1999-09-08 | 2001-03-15 | Genetrol Biotherapeutics, Inc | High level cytokine production with enhanced cell viability |
EP1083230A1 (en) | 1999-09-10 | 2001-03-14 | Academisch Medisch Centrum Amsterdam | Viral replicons and viruses dependent on inducing agents |
US7122180B2 (en) | 2000-10-23 | 2006-10-17 | Children's Medical Center Corporation | DNA vectors containing mutated HIV proviruses |
US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
JP2003012698A (ja) | 2001-06-26 | 2003-01-15 | Toyota Central Res & Dev Lab Inc | モノクローナル抗体 |
ATE515189T1 (de) | 2001-12-10 | 2011-07-15 | California Inst Of Techn | Verfahren zur herstellung von antigenspezifischen lymphozyten |
US20050009180A1 (en) | 2001-12-10 | 2005-01-13 | Lili Yang | Method for the generation of antigen-specific lymphocytes |
ES2384960T3 (es) | 2001-12-18 | 2012-07-16 | Cancer Research Technology Limited | Procedimiento para la generación de líneas celulares proliferativas y que se diferencian |
AU2002226390B2 (en) | 2001-12-22 | 2007-11-15 | 4-Antibody Ag | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
AU2003224725A1 (en) | 2002-03-20 | 2003-10-08 | Brigham And Women's Hospital, Inc. | Hiv therapeutic |
GB2398783A (en) | 2003-02-26 | 2004-09-01 | Antonio Lanzavecchia | A method for producing immortalised human B memory lymphocytes |
RU2005131852A (ru) | 2003-03-14 | 2006-04-20 | Уайт (Us) | Антитела против человеческого рецептора il-21 и их применение |
EP1694360B1 (en) | 2003-11-04 | 2010-08-04 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
ATE474915T1 (de) | 2003-11-19 | 2010-08-15 | Us Gov Health & Human Serv | Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b- zellen |
GB0327384D0 (en) | 2003-11-25 | 2003-12-31 | Queen Mary & Westfield College | Gene therapy |
US20050238626A1 (en) | 2004-04-01 | 2005-10-27 | Lili Yang | Antigen specific T cell therapy |
WO2005123923A2 (en) | 2004-06-17 | 2005-12-29 | Wolfgang Hillen | Inducer specific tetracycline repressor proteins and methods of use thereof |
EP1627563A1 (en) | 2004-08-10 | 2006-02-22 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Means and methods for producing a stabilized cell of interest |
EP1647595A1 (en) | 2004-10-15 | 2006-04-19 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Nucleic acids against viruses, in particular HIV |
US7393923B2 (en) | 2004-11-08 | 2008-07-01 | The Regents Of The University Of California | Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same |
JP5142707B2 (ja) | 2005-02-08 | 2013-02-13 | 一般財団法人化学及血清療法研究所 | 抗体の改良方法 |
AU2006247067B2 (en) | 2005-05-18 | 2012-06-07 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling |
US20090217403A1 (en) | 2005-06-06 | 2009-08-27 | Hergen Spits | Means and methods for generating a t cell against an antigen of interest |
ATE512228T1 (de) | 2005-11-17 | 2011-06-15 | Tet Systems Gmbh & Co Kg | Induzierbare expressionssysteme |
PL2540820T3 (pl) | 2005-12-09 | 2018-05-30 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała |
US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
WO2010113039A1 (en) | 2009-04-03 | 2010-10-07 | Medical Research Council | Mutants of activation-induced cytidine deaminase (aid) and methods of use |
BR112012000953A8 (pt) | 2009-07-15 | 2017-12-26 | Aimm Therapeutics Bv | anticorpos de ligação a bactérias gram-positivas, sequência de ácido nucleico,seus usos e seu método de produção, células isolada ou produtora de anticorpo isolado ou recombinante, composições, e método de isolamento de bactérias |
DK2454283T3 (en) | 2009-07-15 | 2018-05-07 | Aimm Therapeutics Bv | METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
WO2011043643A1 (en) | 2009-10-06 | 2011-04-14 | Medimmune Ltd | Rsv-specific binding molecule |
JP6013356B2 (ja) * | 2010-12-02 | 2016-10-25 | アイム・セラピューティクス・べー・フェー | 高親和性抗体を製造するための手段および方法 |
JP6325451B2 (ja) | 2011-12-02 | 2018-05-16 | アイム・セラピューティクス・べー・フェー | A型インフルエンザに特異的な抗体 |
JP2015506687A (ja) | 2012-01-19 | 2015-03-05 | セラピューティック プロテインズ インターナショナル, エルエルシー | 抗−cd20抗体リツキシマブの安定化 |
UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
-
2015
- 2015-01-30 WO PCT/NL2015/050054 patent/WO2015115892A1/en active Application Filing
- 2015-01-30 US US15/113,563 patent/US10611829B2/en active Active
- 2015-01-30 AU AU2015211480A patent/AU2015211480B2/en active Active
- 2015-01-30 BR BR112016017597A patent/BR112016017597A2/pt active Search and Examination
- 2015-01-30 JP JP2016549244A patent/JP6747975B2/ja active Active
- 2015-01-30 DK DK15704857.0T patent/DK3099709T3/da active
- 2015-01-30 CA CA2938193A patent/CA2938193C/en active Active
- 2015-01-30 EP EP15704857.0A patent/EP3099709B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2938193C (en) | 2023-05-02 |
JP2017504345A (ja) | 2017-02-09 |
CA2938193A1 (en) | 2015-09-06 |
AU2015211480A1 (en) | 2016-08-11 |
JP6747975B2 (ja) | 2020-08-26 |
NZ723331A (en) | 2021-08-27 |
US20170008952A1 (en) | 2017-01-12 |
DK3099709T3 (da) | 2020-02-03 |
EP3099709A1 (en) | 2016-12-07 |
US10611829B2 (en) | 2020-04-07 |
AU2015211480B2 (en) | 2020-05-14 |
EP3099709B1 (en) | 2019-12-25 |
WO2015115892A1 (en) | 2015-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019268150A1 (en) | Isotyping immunoglobulins using accurate molecular mass | |
DOP2018000259A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
CL2020003409A1 (es) | Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154) | |
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
BR112017003236A2 (pt) | anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica | |
ECSP18023386A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
CO2018002446A2 (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
CY1121217T1 (el) | Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων | |
CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
UY32501A (es) | Anticuerpo antagonista específico para el heterodímero alfa4-beta7 | |
CO7151527A2 (es) | Anticuerpos anti-cd79 b e inmunoconjugados | |
AR101400A1 (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
ECSP13012673A (es) | Métodos y composiciones para inmunoterapia para enfermedad neural | |
MX2016012273A (es) | Proteinas de union al antigeno vl que presentan diferentes caracteristicas de union. | |
AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
BR112017009152A2 (pt) | métodos de produção de proteínas de duas cadeias em bactérias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: AIMM THERAPEUTICS B.V. (NL) |
|
B25A | Requested transfer of rights approved |
Owner name: KLING BIOTHERAPEUTICS B.V. (NL) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07K 16/00 , C07K 16/10 Ipc: C12N 5/0781 (2010.01), C07K 16/10 (2006.01), C07K |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] |